
Navidea Biopharmaceuticals, a developer of immunodiagnostic agents and immunotherapeutics, has announced that they will enter into a definitive asset purchase …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

